الفهرس 
CORONAVIRUS DISEASE-19 (COVID-19)Only 14 pages are availabe for public view
 |  | from | 193 |  |  |
| | | from | 193 | | |
Abstract
Abstract:
Background: Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but severe condition that has been observed in pediatric patients following COVID-19 infection. The identification of prognostic markers for MIS-C is crucial for early detection and appropriate management. Two potential prognostic markers that have been studied in relation to MIS-C are pentraxin 3 (PTX3) and procalcitonin.
Aim: To assess serum Pentraxin 3 level in COVID-19 infection pediatric patients and Multisystem Inflammatory Syndrome in Children (MIS-C) related to COVID-19.
Methods: This is a cohort study consisting of (75) children, joined through consecutive method. They were assigned into 3 groups, pediatric patients with COVID-19, Pediatric patients with MIS-C related to COVID-19, as well as healthy controls matching age and gender in both groups. In addition, patients were mainly assessed for serum Pentraxin 3, and Serum Procalcitonin levels by ELISA.
Results: We found that the median PTX3 level was significantly higher in the Covid 19 group than the MISC and control groups with values of (11.8 ng/mL), (5.2 ng/mL), and (1.5 ng/mL), respectively. Additionally, median PCT level was significantly higher in the Covid-19 group than the MISC and control groups with values of (799.6 ng/mL), (691.6 ng/mL), and (0.03 ng/mL), respectively.
Conclusion: it’s concluded that PTX3, and PCT levels significantly increase in Covid-19 patients, and MIS-C patients. Not only that, but they are significantly higher in the Covid-19 group than the MIS-C group.